TABLE 1.
Demographic and clinical data for participants in TB serum biomarker studies using the 4,000-plex (phase II) SOMAscan assay
| Demographic or clinical parameter | Phase II sample set (tested on 4,000-plex) |
|
|---|---|---|
| Training | Blinded verification | |
| No. of samples tested | 504 | 216 |
| South Africa | 198 | 83 |
| Peru | 84 | 22 |
| Vietnam | 90 | 30 |
| Bangladesh | 50 | 40 |
| Zimbabwe | 18 | 15 |
| Uganda | 24 | 0 |
| Colombia | 40 | 26 |
| Active TB, culture confirmed [no. (%)] | 252 (50) | 93 (43) |
| Smear-positive TB, no. | 189 (75% of cases) | 71 (76% of cases) |
| Smear-negative TB, no. | 63 (25% of cases) | 22 (24% of cases) |
| Included in analysis [no. (%)] | 466 (92.5) | 204 (94.4) |
| HIV coinfection [no. (%)] | 170 (34) | 67 (31) |
| Age, yr (range), no.a | 34 (17–76), 446 | 34 (18–79), 199 |
| Gender (% male), no.a | 61.5, 423 | 63.5, 159 |
| Weight, kg (range), no.a | 60 (40–129), 137 | 60 (40–121), 57 |
| Height, cm (range), no.a | 164 (140–189), 155 | 165 (146–188), 70 |
| BMI, kg m−2 (range), no.a | 21.6 (15.3–45.3), 124 | 20.4 (14.6–34.6), 46 |
a
Reported for a subset of the samples only, as indicated by the number of samples.